v
Search
Advanced Search

Publications > Journals > Journal of Clinical and Translational Hepatology > Article Full Text

  • Original Article
  • OPEN ACCESS

Clinical and Genetic Characteristics of Alagille Syndrome in Adults

  • Jianguo Li1,2,#,
  • Haicong Wu3,#,
  • Shuru Chen1,2,
  • Jiahui Pang1,2,
  • Heping Wang1,2,
  • Xinhua Li1,2,*  and
  • Weiqiang Gan1,2,* 
 Author information  Cite
Journal of Clinical and Translational Hepatology   2023;11(1):156-162

doi: 10.14218/JCTH.2021.00313

Abstract

Background and Aims

Alagille syndrome (AGS) is an autosomal dominant multisystem disorder caused by mutations in the JAG1 and NOTCH2 genes. AGS has been rarely reported in adult patients, mainly because its characteristics in adults are subtle. The study aimed to improve the understanding of adult AGS by a descriptive case series.

Methods

Eight adults diagnosed with AGS at our hospital between June 2016 and June 2019 were included in the study. Clinical data, biochemical results, imaging results, liver histopathology, and genetic testing were analyzed.

Results

Three female and five male patients with a median age of 24.5 years at the time of diagnosis were included in the analysis. The clinical manifestations were adult-onset (62.5%, 5/8), cholestasis (50%, 4/8), butterfly vertebrae (62.5%, 5/8), systolic murmurs (12.5%, 1/8), typical facies (12.5%, 1/8), posterior embryotoxon, and renal abnormalities (0/8). Genetic sequencing showed that all patients had mutations, with four occurring in the JAG1 gene and four in the NOTCH2 gene. Six were substitution mutations, one was a deletion mutation, and one was a splicing mutation. Five had been previously reported; but the others, one JAG1 mutation and two NOTCH2 mutations were unique and are reported here for the first time.

Conclusions

The clinical manifestations highlighted by the current diagnostic criteria for most adults with AGS are atypical. Those who do not meet the criteria but are highly suspicious of having AGS need further evaluation, especially genetic testing.

Keywords

Alagille syndrome, Clinical features, JAG1, NOTCH2, Adult

Introduction

Alagille syndrome (AGS) is an autosomal dominant multisystem disorder with variable phenotypic penetrance. It is caused by mutations in genes active in the intercellular NOTCH signaling pathway, including JAG1 encoding the JAGGED1 ligand1,2 and NOTCH2 encoding the NOTCH2 receptor.3 Of the two genes, JAG1 mutations are responsible for about 95% of AGS cases.4 The JAG1 gene contains 26 exons, is located on chromosome 20p12.2, and encodes the JAGGED1 ligand. The ligand binds to the NOTCH transmembrane receptor encoded by NOTCH2 gene. The NOTCH intercellular signaling pathway has been shown to be related to cell fate during development in both invertebrates and vertebrates. The NOTCH proteins are involved in the regulation of development of various mammalian organs such as liver, heart, skeleton, kidney, and others (Fig. 1).5,6 The classical diagnosis of AGS7 is based on the presence of bile duct paucity in liver biopsies and at least three of the following five features, chronic cholestasis, cardiac disease (most commonly peripheral pulmonary stenosis), skeletal anomalies (typical butterfly vertebrae), ocular abnormalities (primarily posterior embryotoxon), and characteristic facial features (broad forehead, deep-set eyes, straight nose, pointed chin). AGS is almost exclusively diagnosed as cholestasis in infancy or early childhood. The prevalence is estimated as one case per 70,000 live births,8 but the availability of molecular genetics for diagnosis has increased the estimate to 1 in 30,000 live births.9 That may still be an underestimate, as some patients do not present with liver disease in infancy. In China, AGS is considered a rare disease, no reports clearly show the disease burden, and is often misdiagnosed in adults for reasons that include lack of awareness and the variable clinical findings. We conducted this retrospective study of AGS in adult patients to better understand the disease and establish a better diagnostic algorithm.

Role of the <italic>JAG1</italic> and <italic>NOTCH2</italic> mutations in the pathogenesis of Alagille syndrome (AGS).
Fig. 1  Role of the JAG1 and NOTCH2 mutations in the pathogenesis of Alagille syndrome (AGS).

Methods

Patients

Eight adult patients with AGS from the Department of Infectious Diseases of the Third Affiliated Hospital of Sun Yat-sen University between June 2016 and June 2019 were included in the study. The diagnosis of AGS was based on the revised criteria described by Turnpenny et al,10 which include presence of a variant of JAG1 or NOTCH2 combined with a positive family history or one of the following, chronic cholestasis, skeletal abnormalities, peculiar facies, ocular abnormalities, renal involvement, or cardiovascular disorders. Informed consent to use the test results for medical research was obtained from the patients. The study conformed to the ethical principles of the Declaration of Helsinki and Good Clinical Practice, as well as Chinese regulatory requirements.

Clinical data were obtained from the patients’ medical records, and included demographic characteristics, symptoms, physical examination results, complications, and laboratory data. The patient characteristics included in the physical examination results were facial features, and the presence of heart murmurs and symptoms typical of chronic hepatitis (e.g., jaundice, liver palms, spider angiomas). Routine evaluation included ultrasonography of the liver and kidneys, radiography of the spine, echocardiography, and spiral computed tomography of the chest. Routine blood and urine routines were performed to rule out common liver diseases and to assess liver and renal function. Cholestasis was defined as serum direct/conjugated bilirubin >1.0 mg/dL (17 μmol/L)11 or serum alkaline phosphatase (ALP) >1.5 times the upper limit of normal (ULN) and glutamyl transpeptidase (GGT) >3 times the ULN.12

Percutaneous liver biopsy

Percutaneous liver biopsies were performed in four cases and the fixed, paraffin-embedded tissue was sectioned and stained for hematoxylin and eosin, Masson trichrome, cytokeratin-7, and cytokeratin-19. The histology was reviewed by liver pathologists. Bile duct paucity was defined as the absence of interlobular bile ducts in at least 50% of the portal tracts in liver specimens containing ten or more portal tracts.13

Genetic variation analysis

Genomic DNA was extracted from 3 mL of peripheral blood leucocytes with QIAamp Blood Midi Kits (Qiagen, Hilden, Germany) following the manufacturer’s instructions. Genes related to the target regions were selected for the panel. Biotinylated 60mer probes (P039-Exome; MyGenostics Inc., Beijing, China) were designed to align with the exons of the genes. Samples were organized into Illumina sequencing libraries, which were enriched for target region-associated genes with the MyGenostics Target Region Enrichment protocol. The captured libraries were sequenced with an Illumina HiSeq 2000 Sequencer (FC-404-2004; Illumina, San Diego, CA, USA).

Statistical analysis

Continuous variables were reported as means and SD or medians. Categorical variables (e.g., age and sex) were reported as numbers and percentages (%). The statistical analysis was performed with SPSS Statistics version 20 (IBM Corp., Armonk, NY, USA).

Results

Clinical characteristics

The patient characteristics are shown in Table 1. Five men and three women with a median age of 24.5 (16–56) years of age at the time of diagnosis were included. One patient (case 1) had positive family history with her mother diagnosed with clinically and genetically confirmed AGS-related cirrhosis. One patient had characteristic facial features, with a broad forehead and posterior embryotoxon. Three patients (37.5%, 3/8) had jaundice since childhood but had not received definitive diagnoses. Five patients (62.5%, 5/8) developed jaundice or hepatic dysfunction in adulthood. Seven patients (87.5%, 7/8) presented with abnormal liver function, half of whom had significant jaundice. Seven patients presented with splenomegaly, but case 3 did not. Systolic murmurs were present in the aortic and pulmonary valve regions in case 2. No sign of structural cardiac disease or vascular malformation was found in any patient. Butterfly vertebrae were found in five of the eight patients (62.5%, Fig. 2). Only one patient had facies characteristic of AGS (prominent forehead and wide intercanthal distance). Posterior embryotoxon was either not reported (2/8 cases) or absent (6/8 cases). No renal abnormalities were found, but kidney stones were present in two cases. Concomitant diseases included decompensated cirrhosis associated with hepatic B in one case, thalassemia in two, and cholecystolithiasis in one.

Table 1

Clinical characteristics of eight adult patients with Alagille syndrome (AGS)

Case12345678
SexFemaleFemaleMaleMaleMaleMaleFemaleMale
Age (years)1618353619205639
Chief complaintJaundiceSkin pigmentation, pruritusAbnormal LF*Abnormal LF*Jaundice/emaciation/Loss of appetiteJaundiceHypodynamia, distentionJaundice
Onset duration1 year10 years3 years10 years8 years3 days6 months1 month
Family historyPNNNNNNN
LiverCholestasisBile duct paucityaCholestasisPortal hypertensionBile duct paucityaCholestasisPortal hypertensionaBile duct paucitya
AngiocarpyNCardiac MurmurNAHAFNNNN
SkeletalNBVBVBVNBVBVN
OcularNNNANANNNN
FacialNPNNNNNN
KidneyNNNAKidney StoneNNNKidney Stone
SplenomegalyPPNAPPPPP
Other featuresNNNDecompensated, hepatitis B, LC/thalassemiaNHBcAb+ThalassemiaCholecystolithiasis

BV, butterfly vertebra; HAF, hepatic arteriovenous fistula; LC, liver cirrhosis; N, negative; NA, not available; P, positive. aPatients with percutaneous liver biopsy.

Biochemical results

Six patients had elevated total and direct bilirubin, four of whom had abnormal ALP/GGT values, and three had elevated serum total bile acid (TBA). Two of the eight patients had elevated alanine aminotransferase (ALT) and four had elevated aspartate aminotransferase (AST). Serum albumin and international normalized ratio (data not shown) were normal in all patients except in case 4 with hepatitis B-related cirrhosis. Two patients had elevated blood lipids (Table 2).

Table 2

Biochemical characteristics of eight adult patients with Alagille syndrome (AGS)

CaseALT (U/L)AST (U/L)ALP (U/L)GGT (U/L)TBA (µmol/L)TBil (µmol/L)DBil (µmol/L)ALB (g/L)CHE (U/L)TG (mmol/L)CHO (mmol/L)
1925671114.683.7↑61.2↑488,5730.763.21
22040↑168↑132↑44.6↑18.36.545.76,4621.176.63↑
3272960230.347.5↑17.2↑52.68,0950.714.55
42333NA23NA48.3↑11.6↑34.2↓NA0.523.12
55125363.340↑15.2↑44.56,8220.583.36
6194↑77↑13399↑329↑335.2↑193.2↑49.44,8881.131.53
72348↑161↑82↑7.79.32.544.36,4501.695.43
857↑92↑140↑28136.4↑548.6↑442↑42.96,5485.9↑5.7↑

ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CHE, cholinesterase; CHO, cholesterol; DBil, direct bilirubin; GGT, glutamyl transpeptidase; NA, not available; TBA, total bile acid; TBil, total bilirubin; TG, triglyceride. ↑, elevated; ↓, decreased.

Histological results

PIBD was found in three patients (cases 2, 5, and 8). PIBD was absent in case 7, who had butterfly vertebrae, abnormal ALP and GGT level, cirrhotic changes ultrasound, and JAG1 mutation was found. Other histological findings included hepatocyte lipofuscin and glycogenosome deposition (Fig. 3).

Butterfly vertebrae in the thoracic and upper lumbar regions.
Fig. 2  Butterfly vertebrae in the thoracic and upper lumbar regions.

X-ray images of (A) case 2 showing butterfly vertebrae (red arrows) and (B) of normal control.

Genetic variation in AGS

Alterations in the JAG1 gene (50%, 4/8) and NOTCH2 gene (50%, 4/8) were identified, and included substitutions in six cases, a deletion in one, and a splice mutation in one. One of the four different JAG1 gene mutations was novel (c.133G>A) and two of the NOTCH2 gene mutations were novel, c.6487G>A, and c.2480-4C>G (splicing). The three novel mutations were confirmed by searching the Human Gene Mutation Database updated on 4 November 2021 and the ClinVar database. The missense and splicing mutations were verified by Sanger sequencing. Genetic testing of both parents of three involved patients showed the mutations were derived from mothers. The mother of another patient was negative for the mutation; the father was not tested. The parents of the other four cases were not tested (Table 3).14–17

Table 3

Distribution of mutations in eight adult patients with Alagille syndrome (AGS)

CaseGeneMutationExonPredicted EffectSourceRelated Reports
1NOTCH2c.6487G>AExon34p.D2163NMotherNovel
2JAG1c.1485_1486delExon12p.C496F fs*9MotherCrosnier, 199914
3JAG1c.133G>AExon2p.V45MNANovel
4JAG1c.133G>TExon2p.V45LNAKohsaka, 200215
5NOTCH2c.6056G>AExon34p.R2019QNA*Eurofins NTD, 201816
6NOTCH2c.2480-4C>GExon16splicingMotherNovel
7JAG1c.133G>TExon2p.V45LNAKohsaka, 200215
8NOTCH2c.2042T>AExon13p.I681NNAKamath, 201217

NA, Not available. *The mother of case 5 had a negative genetic result; the father was not tested.

Discussion

AGS is a genetic disorder caused by mutations in JAG1 and NOTCH2, which are components of the NOTCH signaling pathway associated with the development of multiple organs,18,19 including bile duct and cardiovascular system20,21 Because the disease is most common in childhood and highly variable across patients,22 AGS is underdiagnosed in adults, especially those without a family history. The patients in this study were from 16 to 56 years of age. Most previously published studies describe pediatric patients. With the exception of some case reports, few summaries of the clinical features of AGS in adults are available. To the best of our knowledge, our study is the largest diagnostic series of adult AGS in China.

According to the traditional diagnostic algorithm, AGS should manifest as bile duct paucity and at least three other features, cholestasis, characteristic facies, vertebral anomalies, ocular abnormalities, and cardiovascular malformations. In our cohort, only case 2 met these criteria. The diagnostic criteria for AGS have changed considerably with the development of molecular testing. Kamath et al.23 and Turnpenny et al.10 revised the diagnostic criteria for AGS to include one or more characteristic clinical features and mutations in JAG1 or NOTCH2. Those with a family history of AGS and defects, even in the absence of some clinical manifestations, should be considered to have AGS and evaluated regularly.

As reported in other large cohorts,22,24 butterfly vertebrae were common in our patients, occurring in five (62.5%). However, in contrast to previously reported high cholestasis rates, we found that only 50% of the cases had cholestasis. More importantly, the percentages of congenital cardiac disease (12.5%), vascular anomalies (0%), posterior embryotoxon (0%), and typical facial features (12.5%) were also low in our cohort. It is possible that the lesions in these patients were mild and difficult to identify. Another possibility is that the manifestations of AGS are not the same in adults as in children. Previous studies22,25 have reported renal anomalies in 40–70% of clinically diagnosed AGS, including renovascular disease, tubulointerstitial nephritis, and renal dysplasia or agenesis. Some studies26 proposed that renal abnormalities should be considered as a disease-defining criterion for AGS. However, in this study, renal function (blood urea nitrogen and creatinine) and routine urine tests were normal, and renal ultrasonography found no structural abnormalities of the kidneys.

Children with AGS present with growth and mental retardation.27 Chronic disease and malabsorption of fat because of cholestasis may be causative factors. Other abnormalities, such as pancreatic insufficiency, hypothyroidism, small bowel stenosis, atresia, and tracheal stenosis, have also been reported in AGS.28,29 However, there were no similar findings in our study. Two cases had thalassemia, which we believe may be explained by the high incidence of the disease in Guangdong Province.30 The clinical features of AGS vary widely.31 Some patients have only mild elevations of serum bilirubin, bile acids, or liver transferases, but others have severe cholestasis that eventually leads to liver failure. In our study, all patients had hepatic involvement, but cholestasis occurred in only 50%, consistent with the guidelines for the evaluation of cholestatic jaundice in infants.11 However, in adults, the European Association for the Study of the Liver recommends levels of ALP >1.5 ULN and γGGT >3 ULN as biochemical thresholds for diagnosing cholestatic liver diseases.12 From that perspective, none of our cases met the requirements for the diagnosis of cholestasis.

Bile duct paucity is recognized as a necessary feature of AGS, but some patients are reluctant to undergo a liver biopsy because of its invasiveness, and not all patients who undergo liver biopsy show the absence of intrahepatic bile ducts. In our study, one of the four patients with a liver biopsy did not have bile duct loss, which may have been due to sampling error (Fig. 3). Therefore, liver biopsy is not the gold standard for diagnosis. In addition, the clinical manifestations of some patients, especially adults, are not typical, leading to misdiagnosis. Currently, genetic testing is an important diagnostic tool and perhaps should be considered the gold standard for diagnosis. AGS is a multisystem disorder caused by heterozygous mutations in the JAG1 and NOTCH2 genes.32 Our study found greater involvement of NOTCH2 mutations than it’s been previously reported. In our study mutant NOTCH2 accounted for half of the cases, but in previous reports, JAG1 accounted for a larger proportion, 70–94% of the cases.33–35 Perhaps the difference resulted from the older age of onset in our patients or racial differences. As few reports of specific genetic mutations and variations in adults with AGS have been published,36,37 more studies including patients from different regions and nationalities are needed to verify the results.

Liver biopsies of four patients with Alagille syndrome (AGS).
Fig. 3  Liver biopsies of four patients with Alagille syndrome (AGS).

Compared with normal control tissue, intrahepatic bile ducts were absent in cases 2 and 5, case 8 had an obvious decrease of bile ducts and case 7 had similar bile ducts.

The genotype-phenotype correlations in the literature34 are not well documented. We found wide variation in phenotypic expression in our cohort. It was interesting to note the trend in increased bilirubin levels associated with NOTCH2, and that all patients with JAG1 mutations had butterfly vertebrae, and that only one case with a NOTCH2 mutation had butterfly vertebrae. In addition, one patient with a JAG1 mutation had abnormal cardiac sounds and characteristic facial features, but the other patients did not. However, because of the small sample size, no conclusions can be drawn. Studies of links between genotypes and phenotypes in AGS are ongoing, but no clear connections have been found. Factors that may contribute to the variability of genotypes known to be involved, probably involve a second gene that modifies the effects of a JAG1 or NOTCH2 mutation.32 The search for those genes is underway, and there is evidence that the post-translational addition of sugar moieties (glycosylation and fucosylation) to JAG1 protein has an impact on JAG1-mediated NOTCH signaling. The genes may be involved include Lunatic Fringe (LFNG), Radical Fringe (RFNG), and Manic Fringe (MFNG).38 Ryan et al. found that those genes affected the postnatal growth of bile ducts in mice that were haploinsufficient for both JAG1 and one of the other three genes.

Currently there is no novel treatments for AGS, not to mention genetic therapy. The best option for improving quality of life is to diagnose AGS as early as possible and initiate symptomatic treatment to slow the disease process. Lack of branching and elongation of bile ducts has been reported during postnatal liver growth in a patient with AGS.39 Theoretically, novel treatments targeting the NOTCH signaling pathway might promote formation of new bile ducts, thus improving the symptoms of cholestatic liver disease caused by AGS. The aim of treatment would be to increase the expression of JAGGED1 ligand or the NOTCH2 receptor. Such studies are underway to address the urgent need for those with early stages of liver cholestasis. For those who develop into end stage liver disease, liver transplant will be required. For younger patients, the predicted probability of survival to 20 years of age in all patients is 75%. The probability of survival to age 20 is 80% in patients who did not require liver transplantation.22 However, similar survival estimates of adult patients is not available, more studies are required, and antenatal screening of parents for AGS-related mutations is necessary.

Conclusions

In summary, retrospective study of eight adult AGS patients identified a novel JAG1 mutation and two novel NOTCH2 mutations. Abnormal liver function was the most common initial presenting symptom. Cholestasis was not always the most frequent biochemical characteristic, and bile duct paucity was not seen in some patients. Traditional diagnostic criteria were not appropriate for adults with AGS, in whom the diagnosis should rely more on genetic testing than on clinical features.

Abbreviations

AGS: 

Alagille syndrome

ALP: 

alkaline phosphatase

GGT: 

glutamyl transpeptidase

PIBD: 

presence of paucity of intrahepatic bile duct

ULN: 

upper limit of normal

Declarations

Data sharing statement

The datasets used in the study are available from the corresponding author on reasonable request.

Funding

5010 Cultivation Program of Clinical Research of Sun Yat-sen University (2018024) and Startup Fund for scientific research of Fujian Medical University (2017XQ1205).

Conflict of interest

The authors have no conflict of interests related to this publication.

Authors’ contributions

Drafting of the manuscript (JL), data collection and analysis (HW), figure preparation and verification of the original data (SC), preparation of the tables and verification of the original data (JP), revision of the manuscript for important intellectual content (WG), and design of the study and review of the final manuscript (XL).

References

  1. Li L, Krantz ID, Deng Y, Genin A, Banta AB, Collins CC, et al. Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat Genet 1997;16(3):243-251 View Article PubMed/NCBI
  2. Oda T, Elkahloun AG, Pike BL, Okajima K, Krantz ID, Genin A, et al. Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nat Genet 1997;16(3):235-242 View Article PubMed/NCBI
  3. McDaniell R, Warthen DM, Sanchez-Lara PA, Pai A, Krantz ID, Piccoli DA, et al. NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. Am J Hum Genet 2006;79(1):169-173 View Article PubMed/NCBI
  4. Gilbert MA, Bauer RC, Rajagopalan R, Grochowski CM, Chao G, McEldrew D, et al. Alagille syndrome mutation update: Comprehensive overview of JAG1 and NOTCH2 mutation frequencies and insight into missense variant classification. Hum Mutat 2019;40(12):2197-2220 View Article PubMed/NCBI
  5. Ayoub MD, Kamath BM. Alagille Syndrome: Diagnostic Challenges and Advances in Management. Diagnostics (Basel) 2020;10(11):E907 View Article PubMed/NCBI
  6. Gilbert MA, Loomes KM. Alagille syndrome and non-syndromic paucity of the intrahepatic bile ducts. Transl Gastroenterol Hepatol 2021;6:22 View Article PubMed/NCBI
  7. Alagille D, Estrada A, Hadchouel M, Gautier M, Odièvre M, Dommergues JP. Syndromic paucity of interlobular bile ducts (Alagille syndrome or arteriohepatic dysplasia): review of 80 cases. J Pediatr 1987;110(2):195-200 View Article PubMed/NCBI
  8. Danks DM, Campbell PE, Jack I, Rogers J, Smith AL. Studies of the aetiology of neonatal hepatitis and biliary atresia. Arch Dis Child 1977;52(5):360-367 View Article PubMed/NCBI
  9. Kamath BM, Bason L, Piccoli DA, Krantz ID, Spinner NB. Consequences of JAG1 mutations. J Med Genet 2003;40(12):891-895 View Article PubMed/NCBI
  10. Turnpenny PD, Ellard S. Alagille syndrome: pathogenesis, diagnosis and management. Eur J Hum Genet 2012;20(3):251-257 View Article PubMed/NCBI
  11. Fawaz R, Baumann U, Ekong U, Fischler B, Hadzic N, Mack CL, et al. Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2017;64(1):154-168 View Article PubMed/NCBI
  12. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51(2):237-267 View Article PubMed/NCBI
  13. Ludwig J, Wiesner RH, LaRusso NF. Idiopathic adulthood ductopenia. A cause of chronic cholestatic liver disease and biliary cirrhosis. J Hepatol 1988;7(2):193-199 View Article PubMed/NCBI
  14. Crosnier C, Driancourt C, Raynaud N, Dhorne-Pollet S, Pollet N, Bernard O, et al. Mutations in JAGGED1 gene are predominantly sporadic in Alagille syndrome. Gastroenterology 1999;116(5):1141-1148 View Article PubMed/NCBI
  15. Kohsaka T, Yuan ZR, Guo SX, Tagawa M, Nakamura A, Nakano M, et al. The significance of human jagged 1 mutations detected in severe cases of extrahepatic biliary atresia. Hepatology 2002;36(4 Pt 1):904-912 View Article PubMed/NCBI
  16. VCV000196923.2 - ClinVar - NCBI (nih.gov). Available from: https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000196923.2/?redir=vcv
  17. Kamath BM, Bauer RC, Loomes KM, Chao G, Gerfen J, Hutchinson A, et al. NOTCH2 mutations in Alagille syndrome. J Med Genet 2012;49(2):138-144 View Article PubMed/NCBI
  18. McCright B, Lozier J, Gridley T. A mouse model of Alagille syndrome: Notch2 as a genetic modifier of Jag1 haploinsufficiency. Development 2002;129(4):1075-1082 View Article PubMed/NCBI
  19. Geisler F, Nagl F, Mazur PK, Lee M, Zimber-Strobl U, Strobl LJ, et al. Liver-specific inactivation of Notch2, but not Notch1, compromises intrahepatic bile duct development in mice. Hepatology 2008;48(2):607-616 View Article PubMed/NCBI
  20. Zong Y, Panikkar A, Xu J, Antoniou A, Raynaud P, Lemaigre F, et al. Notch signaling controls liver development by regulating biliary differentiation. Development 2009;136(10):1727-1739 View Article PubMed/NCBI
  21. Boucher JM, Harrington A, Rostama B, Lindner V, Liaw L. A receptor-specific function for Notch2 in mediating vascular smooth muscle cell growth arrest through cyclin-dependent kinase inhibitor 1B. Circ Res 2013;113(8):975-985 View Article PubMed/NCBI
  22. Emerick KM, Rand EB, Goldmuntz E, Krantz ID, Spinner NB, Piccoli DA. Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology 1999;29(3):822-829 View Article PubMed/NCBI
  23. Kamath BM, Ye W, Goodrich NP, Loomes KM, Romero R, Heubi JE, et al; Childhood Liver Disease Research Network (ChiLDReN). Outcomes of Childhood Cholestasis in Alagille Syndrome: Results of a Multicenter Observational Study. Hepatol Commun 2020;4(3):387-398 View Article PubMed/NCBI
  24. Subramaniam P, Knisely A, Portmann B, Qureshi SA, Aclimandos WA, Karani JB, et al. Diagnosis of Alagille syndrome-25 years of experience at King’s College Hospital. J Pediatr Gastroenterol Nutr 2011;52(1):84-89 View Article PubMed/NCBI
  25. Kamath BM, Podkameni G, Hutchinson AL, Leonard LD, Gerfen J, Krantz ID, et al. Renal anomalies in Alagille syndrome: a disease-defining feature. Am J Med Genet A 2012;158A(1):85-89 View Article PubMed/NCBI
  26. Kamath BM, Spinner NB, Rosenblum ND. Renal involvement and the role of Notch signalling in Alagille syndrome. Nat Rev Nephrol 2013;9(7):409-418 View Article PubMed/NCBI
  27. Arvay JL, Zemel BS, Gallagher PR, Rovner AJ, Mulberg AE, Stallings VA, et al. Body composition of children aged 1 to 12 years with biliary atresia or Alagille syndrome. J Pediatr Gastroenterol Nutr 2005;40(2):146-150 View Article PubMed/NCBI
  28. Kamath BM, Piccoli DA, Magee JC, Sokol RJ, Childhood Liver Disease Research and Education Network. Pancreatic insufficiency is not a prevalent problem in Alagille syndrome. J Pediatr Gastroenterol Nutr 2012;55(5):612-614 View Article PubMed/NCBI
  29. Quiros-Tejeira RE, Ament ME, Heyman MB, Martin MG, Rosenthal P, Hall TR, et al. Variable morbidity in alagille syndrome: a review of 43 cases. J Pediatr Gastroenterol Nutr 1999;29(4):431-437 View Article PubMed/NCBI
  30. Red Blood Cell Diseases (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Consensus of experts on diagnosis and treatment of non-transfusion dependent thalassemia in China (2018 edition). Zhonghua Xue Ye Xue Za Zhi 2018;39(9):705-708 View Article PubMed/NCBI
  31. Guegan K, Stals K, Day M, Turnpenny P, Ellard S. JAG1 mutations are found in approximately one third of patients presenting with only one or two clinical features of Alagille syndrome. Clin Genet 2012;82(1):33-40 View Article PubMed/NCBI
  32. Mitchell E, Gilbert M, Loomes KM. Alagille Syndrome. Clin Liver Dis 2018;22(4):625-641 View Article PubMed/NCBI
  33. Cho JM, Oh SH, Kim HJ, Kim JS, Kim KM, Kim GH, et al. Clinical features, outcomes, and genetic analysis in Korean children with Alagille syndrome. Pediatr Int 2015;57(4):552-557 View Article PubMed/NCBI
  34. Spinner NB, Colliton RP, Crosnier C, Krantz ID, Hadchouel M, Meunier-Rotival M. Jagged1 mutations in alagille syndrome. Hum Mutat 2001;17(1):18-33 View Article PubMed/NCBI
  35. Warthen DM, Moore EC, Kamath BM, Morrissette JJ, Sanchez-Lara PA, Piccoli DA, et al. Jagged1 (JAG1) mutations in Alagille syndrome: increasing the mutation detection rate. Hum Mutat 2006;27(5):436-443 View Article PubMed/NCBI
  36. Zhang W, Zhao X, Huang J, Ou X, Jia J. Alagille syndrome: an uncommon cause of intrahepatic cholestasis in adults. Rev Esp Enferm Dig 2019;111(4):323-326 View Article PubMed/NCBI
  37. Jacquet A, Guiochon-Mantel A, Noël LH, Sqalli T, Bedossa P, Hadchouel M, et al. Alagille syndrome in adult patients: it is never too late. Am J Kidney Dis 2007;49(5):705-709 View Article PubMed/NCBI
  38. Ryan MJ, Bales C, Nelson A, Gonzalez DM, Underkoffler L, Segalov M, et al. Bile duct proliferation in Jag1/fringe heterozygous mice identifies candidate modifiers of the Alagille syndrome hepatic phenotype. Hepatology 2008;48(6):1989-1997 View Article PubMed/NCBI
  39. Libbrecht L, Spinner NB, Moore EC, Cassiman D, Van Damme-Lombaerts R, Roskams T. Peripheral bile duct paucity and cholestasis in the liver of a patient with Alagille syndrome: further evidence supporting a lack of postnatal bile duct branching and elongation. Am J Surg Pathol 2005;29(6):820-826 View Article PubMed/NCBI
Copyright © 2023 Authors. This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • Journal of Clinical and Translational Hepatology
  • pISSN 2225-0719
  • eISSN 2310-8819

Article Options

Metrics

Cite this Article

  • © 2024 Xia & He Publishing Inc.
  • Total visits : 2622375
  • Visits today : 3157
Back to Top

Clinical and Genetic Characteristics of Alagille Syndrome in Adults

Jianguo Li, Haicong Wu, Shuru Chen, Jiahui Pang, Heping Wang, Xinhua Li, Weiqiang Gan
  • Reset Zoom
  • Download TIFF